Skip to main content
SpringerLink
Log in

Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP)

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The concentration-time profiles of Doxorubicin (DOXO) from day 0 to day 21 after i.v. infusion of 25 or 30 mg/m2 doxorubicin HCl stealth liposomes (Caelyx®) were investigated in 9 patients receiving combination polychemotherapy with cyclophosphamide, vinorelbine and prednisone. Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax=1.79±1.55 d) with a mean cmax of 4595±2849 ng/ml. A total amount of 12.84±2.47 mg liposomal DOXO in the plasma volume (Vp=2794+537 ml) could be estimated at tmax (=27% of the mean dose of 47.6 mg). Stealth liposomes were eliminated slowly from the blood with a mean t1/2el of 1.9+0.5 days (MRT was 4.6+2.5 days).

AUClast values ranged from 8070 to 33446 ng/ml*d (mean 10987±9339 ng/ml*d). The low plasma clearance (Cltot=4681±2835 ml/day) and the small volume of distribution (Vz=11.7±6.3 l) suggested that stealth-liposomes were stable in the blood at least for 14 days. Polychemotherapy with Hyper-CCVP schedule did not alter the stability of stealth liposomes, but peak levels of DOXO seemed to be somewhat lower compared to regression analysis of literature data (cmax versus dosage range from 20 to 60 mg/m2). Due to clast occurring between day 12 to 18, no indices for an accumulation of the drug in the blood could be found, when liposomes were given every four weeks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bielack S.S., Ertmann R., & Kempf-Bielack G. (1996): Impact of scheduling of toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur. J. Cancer, 32A, 1652

    Article  CAS  PubMed  Google Scholar 

  2. SEQUUS Pharmaceutical Inc. Investigators Brochure (1997): “Doxorubicin encapsulated in stealth liposomes”, pp. 65–70

  3. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Yong A. (1991): Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half lives in-vivo. Biochim. Biophys. Acta, 1066, 29–36.

    Article  CAS  PubMed  Google Scholar 

  4. Huang S.K., Lee K.D., Hong K., Friend D.S., Papahadjopoulos D. (1992): Microscopic localisation of sterically stabilised liposomes in colon carcinoma bearing mice. Cancer Res., 52, 5135–43.

    CAS  PubMed  Google Scholar 

  5. Huang S.K., Martin F.J., Jay G. (1993): Extravasation and transcytosis of liposomes in Kaposi’s sarcoma-like dermal lesions of transgenic mice bearing the HIC tat gene. Am. J. Pathol. 143, 10–14

    CAS  PubMed  Google Scholar 

  6. Northfelt D.W., Kaplan L., Russell J., Volberding P.A., Martin F.J. Pharmacokinetics and tumour localisation of DOX-SL (STEALTH” liposomal doxorubicin) by comparison with Adriamycin in patients with AIDS and Kaposi’s sarcoma. In: Stealth Liposomes (Lasic D and Martin F, eds). Boca Raton, FL: CRC Press 1995: pp 257–66

    Google Scholar 

  7. Amantea M., Newman M.S., Sullivan T.M., Forrest A., Working P.K. (1999): Relationship of dose intensity to the induction of palmar-plantar erythro-dysesthia by pegylated liposomal doxorubicin in dogs. Human Exp. Toxicol., 18, 17–26.

    Article  CAS  Google Scholar 

  8. Shipp M.A. (1993): A predictive model for aggressive Non-Hodgkin’s Lymphoma. New Engl. J. Med., 329, 987–994.

    Article  Google Scholar 

  9. Czejka M.J., Georgopoulos A. (1988): High performance liquid chromato-graphic determination of adriblastin in human plasma, urine, saliva and liver punctuate by column switching for drug monitoring studies. J. Chromatogr. Biomed. Appl., 424, 182–188

    Article  CAS  Google Scholar 

  10. Scientific Tables Geigy, Vol. III, Haematology and Human Genetics (Ciba Geigy Limited AG, Basle, Switzerland) 1983: pp 66–67

  11. Czejka M.J., Schueller J., Linkesch W., Eder I., Zeleny U., Kraule C., Pernegg, C. Serum and tissue concentrations of doxorubicin in patients receiving i.v. mono- and polychemotherapy of encapsulated doxorubicin (stealth liposomes, Caelyx”). 28th Annual Symposium European Society of Clinical Pharmacy, Oct. 1999, Berlin, Abstract No. 60

  12. Dinnendahl V., Tricke, U. (1996): Arzneistoffprofile, Basisinformation über arzneiliche Wirkstoffe, 11. Ergänzung, GOVI Verlag GmbH. Pharmazeutischer Verlag, Frankfurt, Germany

    Google Scholar 

  13. Schuler U., Ehninger G., Wagner, T. (1987): Repeated high dose cyclophosphamide administration in bone marrow transplantation; exposure to active metabolites. Cancer Chemother. Pharmacol., 3, 248

    Article  Google Scholar 

  14. Evans, W.E., Crom, W.R. & Yee, G.C. (1980): Adriamycin pharmacokinetics in children. Proc. Am. Assoc. Cancer Res., 21, 176

    Google Scholar 

  15. Dodion, P., Riggs, C.E., Akman, S.R., Tamburini, J.M., Colvin, O.M. & Bachur N.R. (1984): Interactions between cyclophosphamide and adriamycin in rats. J. Pharmac. Exp. Ther., 229, 51–57

    CAS  Google Scholar 

  16. Dodion P., Akman S.R., Tamburini J.M., Riggs C.E., Colvin, O.M., Bachur N.R. (1986): Interaction between cyclophosphamide and doxorubicin. Meta-bolism in rat, effect of cyclophosphamide aldoketoreductase system. J. Pharmac. Exp. Ther., 237, 271–74

    CAS  Google Scholar 

  17. Urien S., Bree F., Breillout F. (1993): Vinorelbine high affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother. Pharmacol., 32, 231

    Article  CAS  PubMed  Google Scholar 

  18. Jehl F., Quoix E., Leveque D. (1991): Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res., 51, 2073

    CAS  PubMed  Google Scholar 

  19. Allen T.M. (1997) Liposomes: opportunities in drug delivery. Drugs 54, 8–14

    Article  CAS  PubMed  Google Scholar 

  20. Amantea M. Gabizon A. (1998): Pharmacokinetics of Caelyx®, Doxil® (Stealth® liposomal doxorubicin) in patients with breast or prostate cancer. Proc. NCI-EORTC (Amsterdam) Abstract No. 653

  21. Gabizon A., Catane R., Uziely B. (1994) Prolonged circulation-time and enhanced accumulation in malignant exsudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54, 987–992

    CAS  PubMed  Google Scholar 

  22. Northfelt D.W., Francis J.M., Working P., et al. (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization and safety in patients with AIDS related Kaposi sarcoma. J. Clin. Pharmacol., 36, 55–63.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Div. of Haematology, Dep. of Medicine, University Clinic of Graz, Austria

    W. Linkesch, M. Weger & H. W. Auner

  2. Pharmacokinetic and Drug Metabolism Unit Department of Pharmaceutical Chemistry, University of Vienna, Althanstrasse 14, A-1090, Vienna, Austria

    I. Eder, C. Pernegg, C. Kraule & M. J. Czejka

Authors
  1. W. Linkesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Weger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Eder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. W. Auner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Pernegg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Kraule
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. J. Czejka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Linkesch, W., Weger, M., Eder, I. et al. Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). Eur. J. Drug Metab. Pharmacokinet. 26, 179–184 (2001). https://doi.org/10.1007/BF03190394

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190394

Keywords

Search

Navigation